Maintenance of remission with low-dose olopatadine hydrochloride for itch in well-controlled chronic urticaria

Figures & data

Table 1 Baseline characteristics of patients

	10 mg	5 mg	No medication	Overall
n	35	30	32	97
Age (years), mean, range	55.2 ± 14.9	55.0 ± 13.5	59.1 ± 15.1	56.4 ± 14.5
	24–79	28–81	26–83	24–83
Sex (male/female)	31.4%/68.6%	16.7%/83.3%	28.1%/71.9%	25.8%/74.2%
Other allergic symptoms (asthma, rhinitis, conjunctivitis)	61.8%	67.9%	71.0%	66.7%

Figure 1 The study design.

Figure 2 Disposition of the patients.

Figure 3 A comparison of the visual analog scale (VAS) itch scores in the three groups after the standard treatment with 10 mg olopatadine hydrochloride.

Notes: The VAS itch score was more than 50 before the treatment in all the groups, and it decreased to less than 20 in all of the groups after the treatment. There were no significant differences observed between the groups before and after treatment with 10 mg olopatadine. *P < 0.001 compared to the VAS score before treatment with 10 mg olopatadine in each group.

Figure 4 Rate of patients without relapse.

Notes: Visual analog scale itch score being maintained at less than 50 was significantly prolonged in the 5-mg and 10-mg groups compared with the no-medication group (P < 0.005 and P < 0.001, respectively, log-rank test).